Trial Profile
An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of NCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Aug 2022
Price :
$35
*
At a glance
- Drugs Parsaclisib (Primary) ; Bendamustine; Obinutuzumab
- Indications Follicular lymphoma
- Focus Adverse reactions
- Acronyms CITADEL-102
- Sponsors Incyte Corporation
- 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association
- 26 May 2022 According to Incyte Corporation media release, results from this trial will be presented at the upcoming European Hematology Association 2022 (EHA2022) Congress.
- 01 Dec 2021 Status changed from active, no longer recruiting to completed.